Ruth M. Farrell, MD, MA, Marsha Michie, PhD, Christopher T. Scott, PhD, Rebecca Flyckt, MD, and Mary LaPlante, MD
One reason for neglect of women’s health as patients and subjects has been restrictions on uterine transfer of modified human embryos, a boundary that has now been crossed.
AMA J Ethics. 2019;21(12):E1071-1078. doi:
10.1001/amajethics.2019.1071.
When the patient delivers a low-birth-weight infant that requires extensive time in the neonatal intensive, should she be held responsible? Where do we draw the line? More importantly, on what basis do we draw the line?
Anne Drapkin Lyerly, MD, MA and Ruth R. Faden, PhD, MPH
Participation in a research study—in which there are rigorous standards and close monitoring—may be a safer context for the use of medications in pregnancy than the clinical setting, where the evidence base is lacking.
Christina Krudy, MD and Kavita Shah Arora, MD, MBE
Antenatal corticosteroids aren’t as effective in reducing neonatal mortality in low-income as high-income regions due to cultural and health care differences.
AMA J Ethics. 2018;20(3):261-268. doi:
10.1001/journalofethics.2018.20.3.stas1-1803.
The practice of banking sperm from adolescents about to undergo chemotherapy is not universal, which lends support to the argument that parental consent be required for the intervention.
Clinical and psychosocial considerations influence how oncologists approach discussing sperm banking with adolescent patients who are about to undergo chemotherapy and with the parents of those patients.
Nonlegal, judicial, and statutory courses of action are available to patient surrogates and physicians who cannot agree on withdrawal of life-sustaining treatment.